Methods for investigating the Mode of Action (MoA) for rodent liver tumors via constitutive androstane receptor (CAR) activation are outlined here, based on current scientific knowledge about CAR and feedback from regulatory agencies globally. The key events (i.e., CAR activation, altered gene expression, cell proliferation, altered foci and increased adenomas/carcinomas) can be demonstrated by measuring a combination of key events and associative events that are markers for the key events. For crop protection products, a primary dataset typically should include a short-term study in the species/strain that showed the tumor response at dose levels that bracket the tumorigenic and non-tumorigenic dose levels. The dataset may vary depending on the species and the test compound. As examples, Case Studies with nitrapyrin (in mice) and metofluthrin (in rats) are described. Based on qualitative differences between the species, the key events leading to tumors in mice or rats by this MoA are not operative in humans. In the future, newer approaches such as a CAR biomarker signature approach and/or in vitro CAR3 reporter assays for mouse, rat and human CAR may eventually be used to demonstrate a CAR MoA is operative, without the need for extensive additional studies in laboratory animals.
Introduction
The inclusion of information concerning the mode of action (MoA) for rodent tumor formation in the data package for crop protection active substances submitted for registration or re-registration to regulatory authorities is becoming more frequent. Such data should provide dose-response and temporal information to support the MoA (including supporting evidence for each key event) and whether or not the MoA is relevant to humans. A conceptual framework was developed by the World Health Organization -International Programme on Chemical Safety (WHO-IPCS) as described by Sonich-Mullin et al. (2001) to aid in the process of characterizing a proposed MoA and determining the human non-relevance. This framework allows the reviewer to apply a rigorous and transparent approach in the assessment of the weight of evidence for rodent tumor formation and identification of critical data needs. This framework has gone through several iterations, with the most recent in 2014 (Meek et al., 2014) , and the concepts it describes have been adopted by several organizations and agencies. For example, the US Environmental Protection Agency (US EPA) has proposed that the MoA for carcinogenicity can be an integral part of its cancer risk assessment process (U.S. Environmental Protection Agency, 2005) , and the European Chemicals Agency (ECHA) has provided guidance on the use of MoA data in the harmonized classification, labelling and packaging (CLP) process (ECHA, 2015) . In the guidance provided by ECHA, they recommend that the IPCS framework (IPCS, 2007) Although the IPCS Conceptual Framework provides a means for identification of critical data needs and subsequently organizing them, the choice of models and methods to generate the data as well as the amount of data to submit to EU authorities as part of the registration of a an active ingredient is very much up to the individual submitter. This can lead to mechanistic data packages of varying sizes generated using different approaches, which can complicate the assessment of MoA data for a particular compound, unless the reviewer is very familiar with the generally-accepted standards of Biological Plausibility and sufficient Weight of Evidence (components of the IPCS framework). One such example of a MoA where a number of plant protection products, human drugs and industrial chemicals have been shown to produce rodent liver tumors is a MoA via activation of the constitutive androstane receptor (CAR). A recent review captured the state of the science for the CAR MoA as of 2013 (Elcombe et al., 2014) ; it also provided a review of the evidence that mouse or rat liver tumors that occur via a CAR MoA are not relevant to humans based on qualitative differences between the species. However, newer publications continue to shed light on this MoA, and describe additional experimental models that were not reviewed at the time of the Elcombe et al. (2014) review. Therefore, the objective of the present manuscript is to define a minimum set of data that would adequately support a MoA for rodent tumor formation via CAR activation based on the current (2018) state of the science, the principles of the IPCS Framework, and experience with specific experimental models. Necessary components that are outlined in the IPCS Framework, such as disproving alternative MoAs and demonstrating data related to the human relevance of the animal MoA will also be described. It should be noted that it is not the objective of this document to provide compulsory data requirements. The means by which data are generated when embarking on a program of mechanistic studies to test a hypothesized CAR MoA should take the recommendations of this paper into consideration, but the data needs for a specific chemical will need to be sufficiently flexible to handle the unique properties of that molecule, ongoing feedback from EU or other regulatory agencies, plus the emergence of new tools and new knowledge about the CAR pathway. The content of this manuscript and the regulatory needs that it addresses were based upon experience in the EU crop protection environment; however, the content may also be useful to defining a CAR MoA within other regulatory and chemical spaces.
Materials and methods

Background information on CAR activation and other nuclear receptormediated MoAs
Hepatic tumor formation in rodents following life-time exposure to exogenous compounds is a common phenomenon that has been investigated extensively. Several MoAs have been described for liver tumor formation, including DNA reactivity or via a non-genotoxic mode of action that may be either receptor or non-receptor mediated (Cohen, 2010) . A public workshop involving scientists from government, industry and academia was held at the National Institute of Environmental Health Sciences (USA) in September 2010 that explored the MoAs for chemicals causing rodent liver tumors mediated by nuclear receptors (Andersen et al., 2014) . Resulting from that Workshop, a series of publications were issued that described a state-of-the-science view for MoAs via the peroxisome proliferator activated receptor alpha (PPARα) (Corton et al., 2014) , the aromatic hydrocarbon receptor (AhR) (Budinsky et al., 2014) and the constitutive androstane receptor/ pregnane-X receptor (CAR/PXR) (Elcombe et al., 2014) . A fourth publication described the approach used in the Workshop as a whole, and defined terminology for describing the component parts in a MoA that were followed in all of these publications (Andersen et al., 2014) . For these nuclear receptors, each MoA consists of a series of key event (KEs), which are integral to tumor formation, providing the dose is sufficiently high and the duration of exposure is sufficiently long. A MoA can also include associative events (AEs), which are not required for tumor development, but can be used as markers for certain required KEs. In addition, modulating factors (ModFs) may be identified that are not necessary for tumor development, but can modulate the severity or dose response kinetics of KEs leading to tumor development.
The manuscripts from this Workshop provide thorough reviews up to their date of publication on each of these nuclear receptor-mediated MoAs, but scientific publications on each MoA have continued to describe new tools for the study of the underlying biology as well as insights into the mechanisms that occur in different species. For example, Becker et al. (2015) subsequently have described an Adverse Outcome Pathway (AOP) for AhR-mediated liver tumors, building on and expanding the prior publication. The OECD has launched an international programme for development of AOPs, which attempts to capture mode of action information in a prescribed manner that emphasizes a series of readily measurable key event relationships, and encourages scientists to capture these AOPs in an online tool known as AOPwiki as part of the AOP process (Kleinstreuer et al., 2016; OECD, 2013; OECD, 2016) .
In the published proceedings of the nuclear receptor workshop on the CAR/PXR MoA (Elcombe et al., 2014) , the authors could not identify a suitable non-genotoxic PXR activator for which carcinogenicity data were available and hence a MoA was not developed for liver tumor formation by PXR activators. CAR and PXR are often cited together regarding potential MoAs for a specific chemical agent, because extensive cross-talk between these two nuclear receptors has been described (Stanley et al., 2006) , and some agents can activate both CAR and PXR in a particular species (Elcombe et al., 2014) . In fact, PXR is activated by a large array of diverse chemical substances, far more than those that activate CAR (Martin et al., 2010; Timsit and Negishi, 2007; Willson and Kliewer, 2002) . Those chemicals that are pure PXR activators have been shown to increase liver weight after activation but do not increase cell proliferation in the same way that activators of CAR or PPARα do (Shizu et al., 2013; Thatcher and Caldwell, 1994) . Recently, co-administration of a PXR activator along with known activators of other nuclear receptors has shown that while PXR does not produce an increase in cell proliferation on its own, it may enhance the proliferative signals of CAR or PPARα activators (Shizu et al., 2013) . Given the lack of actual tumorigenic key events due to PXR activators alone, the rest of this current publication will focus on the CAR MoA by itself.
Approach of this paper
To assist in clarifying the current state of the art for the MoA via CAR activation, and to describe the experimental models available to demonstrate its key events, a consortium of scientists from the European Crop Protection Association (ECPA) was formed involving scientists actively conducting mechanistic research to demonstrate MoAs for various pesticide active ingredients. The review paper on the CAR MoA by Elcombe et al. (2014) was used as a basis for defining the key events and associative events that are part of this MoA. Building on this publication, the authors also reviewed current examples (2012) (2013) (2014) (2015) (2016) (2017) where mechanistic data were submitted to EU regulatory authorities and also were published in the peer reviewed literature to establish that rodent liver tumors occurred via CAR activation. In particular, MoA data for metofluthrin and nitrapyrin (Deguchi et al., 2009; LaRocca et al., 2017; Yamada et al., 2009 ) were used to illustrate data that are typically generated from mechanistic studies investigating the CAR MoA. Feedback from EU regulatory authorities (or at times regulatory authorities in other geographical regions) was considered, as well as the guidance described in the AOP process (Kleinstreuer et al., 2016; OECD, 2013; OECD, 2016) that is incorporated within an AOP for CAR activation leading to hepatocellular adenomas and carcinomas in rodents (Peffer et al., 2017) . Based on these experiences, the authors identified a "Primary" set of experiments and measurements that registrants typically perform to 1) establish that the CAR MoA is operative for a particular pesticide, and 2) exclude the major alternative MoAs for liver tumors, which is an equally important part of the IPCS weight of evidence framework.
Thus, with this objective in mind, the Results section of this paper proceeds in the following manner: 1) It outlines the major Key Events and Associative Events that are elements of the CAR MoA, as defined within this paper; 2) It provides in tabular form (Tables 2 and 3) and accompanying text, the current approaches to establish a CAR-mediated MoA, as well as newer/emerging methods; 3) the Experimental tools available to accomplish these approaches are reviewed in further detail (in particular within Supplemental File S1 and supporting Figures and Tables); 4) key elements to be included in a Weight of Evidence evaluation including overall weight of evidence, biological plausibility, human relevance assessment are discussed, and finally, 5) two Case Studies with experimental data are presented whereby a CAR MoA has been established for nitrapyrin and metofluthrin.
It is important to mention, that the definition of a "Primary" set of experimental data that is commonly used when establishing that a molecule operates via CAR activation reflects a current state of the science view with established methodologies as of 2017. The scientific methods available to researchers, and the understanding of CAR activation and the subsequent processes leading to liver tumors in rodents, will continue to advance, and thus the current Primary set of techniques/measurements may be supplanted by other approaches in the future. The authors recognize this likely transition, particularly in light of the stated desire to reduce in vivo animal testing and embrace in vitro and other alternative approaches (NAS, 2007) . Therefore, some emerging approaches for the demonstration of a CAR MoA are woven into the Tables, the case studies and the narrative that follows, to illustrate the trends that may become more common in future MoA datasets. Fig. 1 shows the MoA for rodent liver tumors via CAR activation that can be used as an aid when evaluating data in order to establish a CARmediated MoA for active ingredients. Key events (KE) and associative events (AE) are shown based on the outputs of an international workshop on nuclear receptor modes of action (Andersen et al., 2014; Elcombe et al., 2014) . Not all of the possible mechanistic steps discussed by Elcombe et al. (2014) or proposed in subsequent literature are shown, in order to restrain this MoA to a definitive set of readily measurable endpoints that encompass those KEs critical to the progression from CAR activation to liver tumor formation, and that allow differentiation from alternative MoAs. This approach is also consistent with the Adverse Outcome Pathway (AOP) process, for which a CAR Liver Tumor AOP has been described (Peffer et al., 2017) .
Results
Description of the CAR MoA
Although literature is available describing the role of decreased apoptosis, altered epigenetic changes specific to CAR activation, inhibition of gap junction intercellular communication and other possible intermediate steps in the CAR MoA for liver tumor formation (Braeuning et al., 2016; Huang et al., 2005; Moennikes et al., 2000; Phillips and Goodman, 2008) , these have not been included as specific data requirements for the purpose of this exercise due to the absence of data indicating their dependency on CAR activation (Elcombe et al., 2014) and/or consideration that these steps could be associative events along the existing key events pathway. Thus, the need to investigate every potential molecular change within a spectrum of complex responses in hepatocytes was considered beyond the scope of this publication, considering that adequate markers of the progression of key events are already captured in the proposed MoA by generating a minimum data set. In addition, the inconsistent nature of other observations such as decreased apoptosis (Sura et al., 2015) would make it challenging to systematically include data for these endpoints with a high degree of confidence in the overall MoA data package. Consequently, they are not included in the set of Key Events described in Fig. 1 and Table 1 .
It should be noted that in the MoA proposed in the current manuscript, the initial step KE1 (CAR activation) can also be described by the equivalent term "Molecular Initiating Event" (MIE) in the recommended nomenclature of an AOP (OECD, 2016; Peffer et al., 2017) . Similarly, the final step of KE5 (increase in hepatocellular adenomas/ carcinomas) can also be described as an "Adverse Outcome" (AO) in the AOPwiki nomenclature. The authors of this current manuscript have kept the numbering of Key Events simple and numerical (KE1-KE5), which is more generically consistent with the IPCS Framework for a MoA (Meek et al., 2014) . Thus, while the sequence of events is very consistent with the prior published MoA of Elcombe et al. (2014) and the draft AOP for CAR-mediated rodent liver tumors (Peffer et al., 2017) , the numbering and naming is slightly different.
Key events
KE1: activation of CAR (molecular initiating event)
It is known that a small number of agents can activate CAR indirectly (e.g., phenobarbital), by interacting with the EGF receptor and freeing CAR from its tethering complex in the cytoplasm (Mutoh et al., 2009 (Mutoh et al., , 2013 , but a much larger set of chemicals appear to activate CAR by direct binding to its ligand binding domain (Chen et al., 2010; Kublbeck et al., 2011; Omiecinski et al., 2011) . When activated (indirectly or directly), CAR is transported to the nucleus where it dimerizes with the Retinoid X Receptor alpha (RXRα), and this CAR-RXR complex binds selectively to recognition elements on specific CAR-responsive genes.
3.2.2. KE2: up and down regulation of a set of genes secondary to CAR activation
In rats and mice, CAR activation alters the expression of certain genes related to cell cycle control, producing changes resulting in a proproliferative and anti-apoptotic environment. In addition to these genes, CAR activation is known to alter gene expression related to: 1) metabolizing enzymes such as CYP2B and CYP3A isoforms, as well as various conjugating enzymes; 2) gluconeogenesis control; and 3) lipid regulation. These additional gene expression changes and accompanying changes in hepatocytes such as hypertrophy or increased lipid deposition are not related to downstream key events, but can serve as useful markers of a CAR-mediated MoA (Elcombe et al., 2014; Oshida et al., 2015a; Peffer et al., 2007 ) (i.e., they represent associative events-see Section 3.3). the counterparts of liver cell dysplasia that are typically described as large cell change or small cell change in human liver (Thoolen et al., 2010 (Thoolen et al., , 2012 . While these altered foci in the rodent liver are presumed to be preneoplastic, there is experimental evidence that not all foci progress to neoplasia and that some will regress (Bannasch et al., 2003; Williams, 1989) .
KE3: increased cell proliferation
This is a measurable key event in the CAR MoA. For most CAR activators, cell proliferation is observed on a whole liver basis primarily in the first 1-3 weeks after treatment begins, and then returns to a similar rate as in control animals. However, while the hepatocyte labelling index returns to control levels with sustained treatment, overall cell proliferation is still enhanced due to the increase in the total number of hepatocytes per animal. Also, cell proliferation within altered foci in initiation-promotion studies in mice or in rats has been shown to be enhanced by CAR activator treatment at 20-76 weeks after initiation in a dose-responsive manner (Bursch et al., 2005; Klaunig, 1993; Kolaja et al., 1996b) . The time course of a cell proliferation response can be very dependent on the zones of the liver examined (periportal, midzonal, centrilobular; Kolaja et al., 1996a) , and on the specific CAR activator and the species/strain of rodent that is tested (Huang et al., 2005; Kolaja et al., 1996a) .
KE4: increase in foci of altered hepatocytes
In this proliferative environment, a higher number of spontaneously mutated hepatocytes can form, and these cells replicate via clonal expansion to form pre-neoplastic foci. Altered foci are often described based on their staining properties. An increase in eosinophilic foci is most commonly observed after long-term administration of CAR activators (Deguchi et al., 2009; Jones et al., 2009 ), but mixed foci (i.e., including basophilic or clear cells) can at times be observed. Importantly, a documented increase in the number of altered foci in rodent livers may not be identified in a particular study because of the timing of sacrifice(s) and the intrinsic characteristics of the chemical of interest.
3.2.5. KE5: increase in hepatocellular adenomas/carcinomas (adverse outcome)
Eventually, under continued CAR activation, the pre-neoplastic foci clonally expand to form hepatocellular adenomas and carcinomas. • mRNA levels for genes that are CAR mediated, such as Cyp2b10 and Cyp3a11 (mice),
Gadd45b
, and/or Ki67.
• Microarray results showing pathways differentially enriched for CAR-mediated processes (Oshida et al., 2015a ).
• CAR reporter assays (in vitro) -demonstration of KE1 (species-specific).
• Absent or greatly diminished signals (e.g., Cyp activity, mRNA levels, liver weight, liver hypertrophy) in CAR KO animals, to establish that these processes are CAR mediated. Additional related measurements to disprove alternative MoAs, e.g.,:
• No large induction of CYP1A and CYP1B isoforms (not an AhR activator)
• No large induction of CYP4A or palmitoyl-CoA oxidation activity (not a PPARα activator)
• No excessive short-term necrosis (e.g., unlike carbon tetrachloride)
• No excessive liver inflammation or deposition of metals (Cohen, 2010) • Show increased BrdU labelling of hepatocytes (Labels DNA only during S-phase of the cell cycle), OR
• Show increased Ki67 labelling within hepatocytes (Marker that increases in all phases of cell cycle except G0), OR
• Other proven methods such as increased 3 H-thymidine incorporation, or increased EdU labelling of hepatocytes.
KE4: Increased clonal expansion, leading to increased altered foci
Optional No special study required; foci of cellular alteration often (but not always) are observed in histopathology examination of livers in chronic rodent studies.
• May or may not be observed, depending on the timing of sacrifice intervals, number of early decedents, and the specific CAR activator
• Foci typically classified as eosinophilic, clear cell, basophilic.
KE5: Increased hepatocellular adenomas, carcinomas
Required No special study required. Recorded in the course of a chronic/carcinogenicity study.
Human Non-Relevance of the MoA Optional A MoA via CAR activation in mice or rats has been concluded to be non-relevant to humans, based on qualitative differences in response of the hepatocytes in humans vs. rodents (Elcombe et al., 2014; Yamada et al., 2014) . If specific data for the test compound is desired, typical studies to show the differences between rodent and human hepatocytes may include the following:
• In primary hepatocyte cultures (rodent and human): investigation of CYP2B induction (via mRNA levels, enzyme activities or protein levels) AND investigation of cell proliferation (via BrdU labelling index, Ki67 labelling index or a similar endpoint). A marker of cytotoxicity is also an important endpoint, to assure that effects are measured at concentrations (μM) up to a level that is not confounded by excess cytotoxicity and cell death.
• Additional in vivo models that contain humanized forms of CAR, or chimeric mouse models containing human hepatocytes, are being developed and tested, and may provide an alternative to primary hepatocytes (see Supplemental File S1 and Supplemental Table S1 ).
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Associative events
In addition to these Key Events, a small subset of Associative Events is useful in providing support that a particular agent is operating via a CAR MoA (Table 1 and Fig. 1 ). Gene expression changes secondary to CAR activation (KE2) includes the increased expression of certain xenobiotic metabolizing enzymes, including a range of cytochrome P450 (Cyp) enzymes. The pattern and magnitude of induction of specific Cyps and other metabolizing enzymes serves as a biomarker for the respective nuclear receptor that is activated. With CAR activators, Cyp2b is a predominant isoform that is induced, with lesser induction of Cyp3a isoforms. Translation of these gene signals into microsomal proteins leads to increased CYP2B and CYP3A enzyme activities and protein levels in the hepatocytes (AE1). The induction of these Cyp enzymes within the endoplasmic reticulum leads to hepatocellular hypertrophy, a characteristic increase in cell size (AE2), and then an increase in liver weight (AE3). Hepatocellular hypertrophy and increased liver weight are not uniquely caused by CAR activation, as other mechanisms including PPARα activation or AhR activation can also produce these changes. However, these alternative MoAs typically produce patterns of Cyp induction that are different from that seen with CAR activation (Budinsky et al., 2014; Corton et al., 2014) .
Minimum dataset, and further supporting information, for demonstrating a CAR MoA
When proposing a CAR MoA for liver tumors induced by a test compound, there are critical parameters to be included in the final mechanistic data package, which should (at a minimum) include demonstration of the molecular initiating event (i.e., CAR activation, KE1) and the obligatory key event of increased cell proliferation (KE3), while excluding other possible MoAs. If additional studies or assays are incorporated into a package of MoA work, the weight of evidence supporting the MoA in animals can become greater, in accord with the Bradford-Hill criteria that are part of the IPCS Framework, including:
• Empirical support (including dose-concordance and time-concordance of Key Events and the adverse outcome)
• Strength and consistency of the data (e.g., evidence across multiple studies, and across multiple related measurements)
• Essentiality of the key events (e.g., when the initial Key Event or subsequent key events are blocked, are the downstream events absent or attenuated?) For the well-described MoA of CAR activation leading to mouse and/or rat liver tumors, data to demonstrate the essentiality of the key events via studies in CAR knockout mice or via use of silencing RNA • Whole mouse (rat) microarray results showing pathways differentially enriched for CAR-mediated processes (Oshida et al., 2015a ).
• May include metabolic enzyme induction pathway changes and cell cycle/cell proliferation pathway changes Additional related measurements to disprove alternative MoAs:
• [same as shown in Table 2 Human Non-Relevance of the MoA Optional A MoA via CAR activation in mice or rats has been concluded to be non-relevant to humans, based on qualitative differences in response of the hepatocytes in humans vs. rodents (Elcombe et al., 2014; Yamada et al., 2014) . If specific data for the test compound is desired, some emerging methods to compare rodent vs. human responses include:
• Primary hepatocyte cultures (rodent, human) -see Table 2 .
• Hepatocyte spheroids, co-cultures with non-parenchymal cells and other commercial systems offering longer lifetimes than primary hepatocyte cultures (max. 4 days survival).
• Chimeric mouse models containing human hepatocytes (see Supplemental Table   S1 ). For each of these in vitro or in vivo systems, the ability to accurately measure an increase in CAR-mediated markers such as Cyp2b mRNA or enzyme activity (in rodent and human), and the cell proliferation response (rodent-specific) with model compounds needs to be demonstrated. a Short-term in vivo studies conducted during the course of compound development (including subchronic studies) can be designed to yield samples suitable for these later analyses.
b Possibly, in vitro studies with primary hepatocytes or commercial hepatocyte cultures representative for the test species/strain may yield microarray data or mRNA evaluation vs. controls. However, the similarity of the cultured cells to hepatocytes in vivo can vary greatly with time, and appropriate proof of similarity would need to be established.
(siRNA) has been clearly demonstrated for model compounds such as phenobarbital and TCPOBOP (4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3′,5,5′-tetrachloro-1,4-bis(pyridyloxy)benzene), as well as for some plant protection products such as sulfoxaflor, fluopyram, nitrapyrin and metofluthrin (Elcombe et al., 2014; LeBaron et al., 2013; Peffer et al., 2017; Yamada et al., 2009) . Therefore, an appropriate balance is needed between generating a sufficient weight of evidence for a new, suspected CAR activator, versus expending unreasonable amounts of animals, time and money if one were to reproduce all of the experimental models that have been tested with these well-studied CAR activators. In addition, multiple methods are available and in current practice today that can be used successfully to achieve the same objective of demonstrating a particular Key Event. Therefore, this section will outline a set of current approaches ( Table 2 ) that can be used in some combination to demonstrate a minimum but sufficient data set for a CAR MoA, and it will also summarize the newer, emerging methods ( Table 3 ) that can be used to achieve the same objective(s). The current experimental approaches (as of 2017) that are typically used to generate data in support of a CAR-mediated MoA for rodent liver tumors are described in Table 2 . In this table, the "Primary" approach that can be used to generate sufficient data to demonstrate one Key Event (or a group of Key Events and Associative Events) is indicated. "Other means" of demonstrating certain Key Events and/or Associative Events are also listed in Table 2 , and the generation of data via one of these other approaches in addition to data via the Primary approach will add to the overall weight of evidence supporting that particular MoA. However, the need for this added evidence must be balanced against increasing complexity, cost and animal usage. Where appropriate, accompanying measurements that disprove some of the alternative MoAs are also listed in Table 2 , and assays to disprove most of the alternative MoAs can be incorporated into the same mechanistic study (or studies).
The most compelling MoA data will be those generated in the same species, strain and sex of animal in which the tumors were observed following life time treatment with the test compound. If practical, the same test diet and age/source of animal should also be used in the mechanistic studies. In cases where both sexes were affected, in the interest of animal ethics, information gathered using just one sex that is representative of the responses in both males and females should be sufficient. Similarly, if liver tumors are observed for a test material in two species (i.e., mice and rats), a minimum data set could be generated to demonstrate the full MoA in one species, as long as some evidence is provided that indicates the same MoA is operative in the other species. For example, Associative Events (e.g., subchronic liver pathology; liver weight changes; CYP2B induction) may give sufficient evidence of the same MoA being operative, avoiding the need for excessive duplication of data and animal use. Another consideration when designing MoA studies for a suspected CAR activating compound is testing at appropriate dose levels and time intervals. Typically, the dose levels should cover the achieved dose level(s) that caused a tumor outcome in the long-term rodent study, and at least one lower dose where tumors were not observed, along with a concurrent untreated negative control group. Testing at these tumorigenic and non-tumorigenic dose levels is usually necessary in order to satisfy the modified Bradford-Hill criteria, Fig. 1 . A mode of action for rodent liver tumors via CAR activation, suitable for establishing a minimum regulatory dataset. Key events (KE) and associative events (AE) are shown, based on the outputs of an international workshop on nuclear receptor modes of action (Andersen et al., 2014; Elcombe et al., 2014) . Not all of the possible mechanistic steps discussed by Elcombe et al. (2014) or proposed in subsequent literature are shown, in order to refine this MoA to a definitive set of measurable endpoints, and outline a set of experimental data to demonstrate these quantifiable events. The differing Levels of Organization shown (Macromolecular up through Individual) are consistent with the recommendations (AOPwiki.org) for defining a sequence of events leading from a Molecular Initiating Event to an Adverse Outcome (OECD, 2013).
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The duration of a MoA study or mechanistic measurements within guideline subchronic or chronic toxicity studies should include time intervals when the key events or associative events typically occur, which may differ slightly depending on the test compound or strain of animal. Examples of dose-response concordance and time concordance of key events with known CAR activators and plant protection products are available in published literature (Elcombe et al., 2014; Peffer et al., 2017) , and in this current publication for the model compounds nitrapyrin and metofluthrin (see Case Studies).
A typical minimum dataset would include demonstration of:
3.4.1. CAR activation (KE1) and altered gene expression secondary to CAR activation (KE2) Traditionally this is accomplished by measuring gene transcript levels (KE2), by demonstrating AE1, i.e., showing increased liver enzyme activity and/or protein that is diagnostic of CAR activators, plus evidence for at least one other related key event or associative event ( Table 2 ). The expected pattern is that the fold-change increase in Cyp2b mRNA levels or CYP2B enzyme activity will be greater than the increase in Cyp3a mRNA levels or CYP3A enzyme activity. These measurements can be accomplished in liver samples from subchronic toxicity studies (stored frozen), or as part of an in vivo short-term MoA study and can include measurement at the transcript, protein or enzyme activity level. When measuring mRNA levels it is important to note that in addition to Cyp2b and Cyp3a, other species-specific isoforms may also be induced (e.g., Cyp2c55 in mice), which, although not critical for MoA demonstration, could provide additional support (Oshida et al., 2015a; Tojima et al., 2012) . Cyp enzyme activity is generally performed using microsomes isolated from the treated animals. CYP2B isoform activity is often demonstrated via PROD and/or BROD activity measurements, and CYP3A activity is often demonstrated via BQ and/or testosterone 6-β-hydroxylase activity, as described further in the Experimental Tools section of this paper (Supplemental File S1). A lack of induction of CYP2B/CYP3A enzyme activity (e.g., no increase in PROD or BROD activity) does not necessarily preclude CAR activation as KE1. If other available data (e.g., increased liver weight coupled with hepatocellular hypertrophy) suggest that the molecule may be a CAR activator, the experimenters may also need to explore changes in mRNA or protein levels, since some CAR activating compounds have been shown to inactivate CYP2B enzymes and thus block the expected increase in PROD/BROD activity, despite large increases in expression of the Cyp2b mRNA and protein (LaRocca et al., 2017; LeBaron et al., 2013) .
Data supporting both KE1 and KE2 can be obtained by investigating changes in gene expression in the liver of treated mice or rats (i.e., KE2). The relative expression of mRNA levels can be measured by focusing on specific CAR-responsive genes, such as Cyp2b10 in mice and Cyp2b1/2 in rats by techniques such as qRT-PCR. Other CAR-responsive genes that are related to cell cycle control or apoptosis control (e.g., Gadd45b and Ki67) may also be of interest, but these can vary depending on the species, strain and test compound and are not specific to CAR activation. Alternatively, changes in the entire array of genes in mice or rats can be investigated by techniques such as microarrays or RNAseq. These whole genome methods can reveal statistically-altered pathways using pathway mapping tools, as well as changes in individual genes such as those described above.
Additional support for KE1 and KE2 can be obtained when standard histopathology examination of the liver demonstrates increased hepatocellular hypertrophy (AE2), which may be zonal in nature (e.g., centrilobular is most common). Hepatocellular hypertrophy will also typically cause an increase in liver weight (AE3) at the same dose levels. Furthermore, depending on the compound, additional histopathology changes may be observed that are still consistent with a CAR-mediated MoA. For example, reduced glycogen deposition, increased lipid vacuolation, and pigment deposition are somewhat non-specific findings that can occur for certain CAR activators (Hall et al., 2012; Moreau et al., 2008; Peffer et al., 2007) . In addition, a small increase in the incidence of mild to moderate single-cell necrosis can sometimes occur, particularly after longer-term treatment of mice with CAR activators (Hall et al., 2012; Peffer et al., 2007) . However, more severe/diffuse necrosis in the liver, particularly if seen in studies of 1-28 days duration, suggests that an alternative MoA via cytotoxicity might be operative for that molecule (Hall et al., 2012) .
Increased hepatocellular proliferation (KE3)
As shown in Table 2 , demonstration of KE3 is a Primary endpoint that needs to be established as part of a MoA dataset. Although the increase in proliferation is not unique to the CAR MoA, the temporal profile of cell proliferation can provide indications of a CAR MoA. Specifically, for most CAR activators, the burst of cell proliferation on a whole liver basis is observable early, during days 1-28, but dissipates back to a background labeling index thereafter. However, the overall number of replicating hepatocytes stays elevated due to the increased number of cells in the treated livers as a result of the initial wave of proliferation, and specialized studies have demonstrated that increased cell proliferation signals still occur within altered foci at later time intervals (Bursch et al., 2005; Kolaja et al., 1996b) .
KE4 (increased altered foci) and KE5 (increased adenomas/ carcinomas)
These later key events are observed in the standard rodent carcinogenicity studies and are likely therefore to be the impetus for conducting the MoA investigations, and consequently these KEs do not require a special MoA study. The appearance of increased altered foci, often as eosinophilic foci, occurs with model CAR activators such as phenobarbital or TCPOBOP and is part of the known progression of hepatocytes from normal phenotypes/genotypes to tumor phenotypes/ genotypes (Huang et al., 2005; Lake, 2009; Yamamoto et al., 2004) . However, a documented increase in the number of altered foci at the tumorigenic dose level may at times not be observed, depending on the time of interim sacrifices, the number of early decedents and other properties of the particular compound. For example, a chemical that produces a marginally higher number of adenomas/carcinomas after lifetime feeding to mice may not show a statistically significant increase in the pre-neoplastic altered foci.
Integral to a mechanistic package is the exclusion of alternative MoAs that may be responsible for the tumors (Meek et al., 2014) , and a number of modes of action have been identified for liver carcinogenesis (Cohen, 2010) . A list of these alternative MoAs and the types of data needed to disprove each alternative MoA are provided in Table 4 . If these data are not already available in the toxicology database, one may need to generate data to address these alternate MoAs, typically using the species and strain where liver tumors were observed. If CAR knockout models are used, the background rodent strain may be different to that in which the liver tumors were observed. In this case some confirmation that the wild-type strain upon which the KO model is based is responsive to the early key events is needed. General guidance on the types of data that can be generated for each alternative MoA is included in Table 4 . In practice, some alternative MoAs can be excluded if they are not pertinent to the compound in question (e.g., the compound is not designed to inhibit HMG-CoA-reductase like the statins), or based on findings seen in the relevant repeat dose studies (e.g., a lack of evidence of cytotoxicity, inflammation, or signs of estrogenic effects). In other words, some of the existing repeated dose data should be re-R.C. Peffer et al. Regulatory Toxicology and Pharmacology 96 (2018) 106-120 examined to rule out alternative MoAs. Where possible, additional data from a short-term MoA study that helps to preclude the alternative MoAs via specific enzyme activity measurements, transcriptomic profiles or other clinical measurements can provide even greater assurance in dismissing the alternatives.
Data on human non-relevance of the CAR-Mediated MoA
Data concerning human non-relevance is often provided in data packages for crop protection active substances. This is currently done despite a large body of evidence indicating that this MoA is qualitatively not relevant for humans (e.g., Elcombe et al., 2014; Yamada et al., 2014) , supported by epidemiology data with the prototypic CAR activator phenobarbital (e.g., Friedman et al., 2009; IARC, 2001; La Vecchia and Negri, 2014; Whysner et al., 1996) . In these epidemiology studies, patients with epilepsy received phenobarbital for many years at doses producing plasma concentrations similar to those that are carcinogenic in rodents, and the results indicated that there is no evidence of a specific role of phenobarbital in human liver cancer risk. Further, experimental data in Syrian hamster, guinea pigs, non-human primates and humans have demonstrated that hepatocytes from these species (unlike mice and rats) do not respond to CAR activator treatment with an increase in cell proliferation, and lifetime treatment of Syrian hamsters with phenobarbital (Diwan et al., 1986) did not produce any increase in liver tumors (as summarized in Elcombe et al., 2014) .
Based on these established differences between the species, generation of data with a test item to address human non-relevance of CARmediated liver tumors is listed as "Optional" in Table 2 . However, until regulatory authorities (e.g., ECHA, EPA) list the CAR MoA as another example of a MoA that is not relevant to humans, many registrants will want to consider generating test-item specific data that confirms this species difference. With time, as more datasets are reviewed that further confirm the qualitative difference between humans and rodents in the key events of this CAR MoA, these additional studies to demonstrate human non-relevance should become unnecessary for each new molecule.
As shown in Table 2 , a typical study will consist of primary hepatocyte cultures from the responding species (mouse or rat) and from human liver (either freshly prepared or cryopreserved). A preferred approach is to test up to the highest concentration that does not produce excessive cytotoxicity or compound precipitation, which may be established in a preliminary set of incubations. Endpoints of Cyp2b induction (which may be affected in both rodent and human hepatocytes) and cell proliferation (which is typically only increased in rodent hepatocytes) are then assessed at a range of concentrations. Use of positive control compounds, including EGF which produces an increase in cell proliferation in both human and rodent hepatocytes via a direct mitogenic response (Yamada et al., 2014) , is recommended to demonstrate appropriate responsiveness in the experimental systems. In terms of the minimum number of human donors to be used, extensive prior experience with both positive control agents such as phenobarbital and with pesticidal active ingredients (Lake, 2017 ) has demonstrated consistency across many donors in the lack of known CAR activators to produce a proliferative response in human hepatocyte cultures. Therefore, since no reasonable number of human donors could fully provide experimental data across all ethnic, sex, age and genetic polymorphisms, the recommendation for this type of study from the current authors where cell proliferation is the key experimental output (via DNA labeling methods) is that a single human donor is an appropriate source for a primary hepatocyte experiment, as long as the design and reporting includes: 1) disclosure of the sex, age and disease/drug history of the donor; and 2) concurrent testing of appropriate negative and positive controls to demonstrate the responsiveness of the human hepatocyte system (including a known mitogen such as EGF). However, an appropriate number of replicates should be tested for both the human hepatocyte and rodent hepatocyte cultures to achieve sufficient power in statistical comparisons vs. an untreated control group as a part • Oshida et al. (2015a) have reported that CAR activators suppress the activation of PPARα, resulting in decreases in palmitoyl CoA oxidase.
• Parkinson et al. (2006) have reported that small increases in lauric acid 12-hydroxylase activity by CAR activators and this needs to be contrasted to very large increases in lauric acid 12 hydroxylase as a marker of CYP4A activity by PPARα activators (> 10 fold changes).
Enzyme induction (AhR) AhR activators induce Cyp1a mRNA and cause substantial increases in EROD activity (a marker for CYP1A) in rodent liver microsomal preparations.
• Small increases in EROD by CAR activators have been demonstrated previously (Sun et al., 2006) .
• Large increases are seen with AhR activators (Budinsky et al., 2014) .
Statin like
Can be excluded if the molecule was not designed to inhibit 3-hydroxy-3-methylglutaryl Coenzyme A reductase (HMG-CoAreductase) activity. Absence of effects such as decreased cholesterol levels in short-term rodent studies may also be useful; however, rodents (unlike humans) do not show a prolonged reduction in cholesterol following administration of statins (MacDonald and Halleck, 2004) .
Cytotoxicity (including metal overload such as iron and copper)
Hepatic cytotoxicants can be dismissed based on histopathology and/or clinical chemistry data from relevant studies.
• lack of evidence of elevated hepatic damage and/or clinical chemistry markers (e.g., ALT, AST)
• lack of histopathological evidence of sustained inflammation, necrosis or regenerative proliferation in the liver
If needed, lack of staining for iron overload with Prussian blue can help exclude this particular mechanism.
Infection
Can be dismissed based on lack of evidence of infection (including increased leukocyte counts), or lack of regenerative proliferation associated with inflammation from toxicology database.
Increased apoptosis Using existing histopathology data to dismiss evidence of increased apoptosis.
Estrogenic activity A weight of evidence from the toxicity database and/or published literature may be sufficient to address this MoA, including a lack of effects on estrogen-sensitive tissues and/or estrogen-mediated endpoints.
R.C. Peffer et al. Regulatory Toxicology and Pharmacology 96 (2018) 106-120 of the experimental design. Newer models that can be used to demonstrate species differences in the response to a CAR activating compound are listed in Table 3 , and discussed further in Supplemental File S1 (Experimental tools). In addition to primary hepatocyte cultures, various in vitro liver co-culture systems are available (e.g., spheroids, co-cultures with non-parenchymal cells) that provide a system that retains normal hepatocyte morphology for at least 2-3 weeks, whereas primary hepatocyte cultures can only be treated for 4-5 days. However, methods to reliably demonstrate the key endpoints of Cyp2b induction and cell proliferation within these systems will need to be refined and published when exploring the utility of these rodent and human hepatocyte systems. Chimeric mouse models containing human hepatocytes have been demonstrated to produce an appropriate response to phenobarbital in one of the available chimeric models (Yamada et al., 2014) , and offer promise as an in vivo tool. However, there are disadvantages to this system, including high cost of the chimeric mice (currently) and the uncertain impact of an immunologically compromised model on which these chimeric mice are based (as reviewed by Scheer and Wilson, 2016) .
Experimental tools
Numerous tools can be used to generate the data necessary to support a CAR MoA, and a range of tools available are presented in detail in Supplemental Section S1. In accordance with the approach recommended by the Adverse Outcome Pathway (AOP) initiative sponsored by OECD (AOPwiki.org), these tools are described below moving from the smallest biological unit up through increasing levels of biological organization, specifically:
Within the scope of discussion of these experimental tools, Supplemental Section S1 describes both current methods used in exploring a CAR MOA, and emerging methods. Any one specific technique (depending on the month and year it is used) might be considered either a "current method" or a "new/emerging technique", and therefore this Supplemental section does not rigorously try to sort each experimental tool into one or the other box. Instead, a detailed review of methods that can be used currently is described, and the reader is referred to Table 2 (Current approach for data generation) and Table 3 (Emerging approaches) plus the text that describes them for an approximate set of assignments.
Overall weight of evidence
The preceding sections and supporting Tables have outlined the typical datasets that registrants are able to produce currently to support a MoA for rodent liver tumors via activation of the CAR nuclear receptor. As described in the IPCS Conceptual Framework (Boobis et al., 2006; Meek et al., 2014) , the overall weight of evidence can then be assessed for the following three questions:
1. Is the weight of evidence sufficient to establish a MoA in animals? 2. Can human relevance of the MoA be reasonably excluded on the basis of fundamental, qualitative differences in key events between animals and humans? 3. Can human relevance of the MoA be reasonably excluded on the basis of quantitative differences in either kinetics or dynamic factors between animals and humans?
For a particular test item, the first question regarding the animal MoA is assessed taking into account dose concordance, appropriate temporal associations, strength/consistency of the effects across multiple studies, biological plausibility and consideration of alternative MoAs. If sufficient weight of evidence is available to establish that the MoA for a particular test item is via CAR activation (Fig. 1) , then the questions of qualitative or quantitative relevance of the MoA to humans are considered. The panelists from the 2010 Nuclear Receptor Workshop that eventually published their findings in the Elcombe et al. (2014) paper concluded that for a model CAR activator such as phenobarbital, the CAR MoA was non-relevant to humans based on fundamental qualitative differences between mice/rats and humans. This conclusion was based on extensive data with PB and other CAR activators that showed:
• While CAR activators such as PB can cause associative events in human liver such as Cyp induction and hypertrophy, they do not produce the causal key events of increased cell proliferation (KE3), increased altered foci (KE4) or tumors (KE5).
• Adding further weight, the cell proliferation response and eventual development of foci and tumors seem to be unique to mice and rats. Syrian hamsters did not show cell proliferation effects in multiple studies, and they did not develop liver tumors in a long-term studies with PB at a dose level (500 ppm in drinking water) that produced tumors in mice (Diwan et al., 1986) . Additional in vitro or in vivo data in hepatocytes from guinea pig, non-human primate and humans further supported these conclusions (Elcombe et al., 2014) . In addition, multiple epidemiology studies with PB that included lifetime exposures in epileptic patients have shown no clear associations of PB treatment with cancer in humans (La Vecchia and Negri, 2014; Whysner et al., 1996) .
For a new test item, providing the type of experimental data described in this manuscript (e.g., see Table 2 ) should be followed by a consideration of the weight of evidence via the IPCS Framework, including the same steps outlined above. While preparing experimental data that shows a lack of responses in human liver cells is listed as optional (e.g., see Tables 2 and 3 ) because many studies with model CAR activators have established that human livers do not respond in the same way as rodent livers, many registrants will include data for human hepatocytes and/or other systems to provide direct evidence for their test item. If data that are concordant with the previous published literature are obtained, and a sufficient weight of evidence for a CAR MoA are provided, then human relevance of the rodent liver tumors can likely be excluded based on qualitative differences between the species (Elcombe et al., 2014) .
In addition, for some molecules the data in long-term rodent studies will show that the CAR-mediated tumor response was only obtained at dose levels that are clearly in excess of a Maximum Tolerated Dose (> MTD). This conclusion might be based on factors such as excessive mortality, saturation of blood kinetics or excessive target organ toxicity (e.g., liver weights > 25-100% higher than controls and resultant nonspecific, subcapsular necrosis of the liver after longer treatment intervals) (OECD, 2008; U.S. Environmental Protection Agency, 2003; U.S. Environmental Protection Agency, 2005) . For example, chronic liver necrosis secondary to excessively large increases in liver weight and liver size, has been described previously (Hall et al., 2012; Maronpot et al., 2010) , and can lead to liver tumors following regenerative hyperplasia. This necrosis has been shown to occur via mechanical damage to the outlying regions of the liver, or due to poor oxygen flow and nutrient/waste transport in overly enlarged hepatic lobules. Hall et al. (2012) noted that relative liver weights > 150% of control values in short-term studies are a useful standard for predicting that the dose level is likely to exceed the MTD if continued long-term. In these cases where tumors are only observed at a dose in excess of the MTD, the rodent liver tumor formation could be considered non-relevant to human exposure levels without the need for extensive MoA R.C. Peffer et al. Regulatory Toxicology and Pharmacology 96 (2018) 106-120 experiments, if (for example) anticipated human exposures are > 100-fold lower than the rodent dose level and the excessive dosing would never be possible in human exposure scenarios (Foran, 1997; U.S. Environmental Protection Agency, 2003; U.S. Environmental Protection Agency, 2005) . Operationally, the MTD dose ideally produces some minimal signs of toxicity, such as slight depression of body weight gain (not more than 10%), normally without causing tissue necrosis or metabolic saturation, and without substantially altering normal life span due to effects other than tumors (OECD, 2008) . Conversely, it is conceivable that a molecule that shows strong potential for activation of CAR in rats or mice based on in vitro assays may fail to produce marked changes in the liver in vivo if lack of absorption or instability of the test substance after ingestion occurs. In such cases, some knowledge of the toxicokinetics of the test substance would help to determine if this might be a factor in that substance's MoA. However, the series of Key Events and Associative Events depicted in this manuscript (Fig. 1, Table 1 ) do not include these toxicokinetics and exposure considerations, in the interest of simplifying the approach to this MoA and the needed data to demonstrate it. By keeping the exposure route and dosing in typical MoA studies close to the methods that were used in the long-term oncogenicity studies, the net effect of exposure to the test substance can be assumed to match the effects that led to an increase in liver tumors.
Case studies -CAR MoA datasets for crop protection products
As an aid to the understanding of current datasets that can demonstrate a CAR activation MoA, two Case Studies are provided. The examples for nitrapyrin (in mice) and metofluthrin (in rats) utilize some of the same techniques, as well as some differing techniques, to achieve the same goal of attaining sufficient weight of evidence to establish the rodent MoA.
Case study 1 -nitrapyrin tumor MoA in mice
Nitrapyrin (2-chloro-6-trichloromethyl pyridine) is a nitrification inhibitor that lowers the loss of nitrogen fertilizers from the soil, enhancing the uptake of ammonia nitrogen by crops. In a 24-month study, nitrapyrin caused an increased incidence of hepatocellular adenomas/ carcinomas in female B6C3F1 mice at dose levels of 125 and 250 mg/ kg/day, with no effect at 75 mg/kg/day. It also caused an increase of hepatocellular adenomas and carcinomas in male B6C3F1 mice at the high dose of 250 mg/kg/day. In a retrospective MoA experiment, groups of male B6C3F1 mice were dosed for 4, 7 or 14 days with nitrapyrin at dose levels of 0, 75, 250 and 400 mg/kg/day, and a further set of male mice were treated for 14 days followed by a 21-day recovery period. The dose concordance and time concordance for data that support the MoA for nitrapyrin-induced mouse liver tumors are shown in Table 5 .
The activation of CAR by nitrapyrin (KE1) was determined in an indirect manner based on demonstration of increased transcription of CAR responsive genes (Cyp2b10) by qRT-PCR, increased expression of CYP2B10 protein, and increased liver weight and hepatocellular hypertrophy at ≥250 mg/kg/day. PROD activity as a marker of increased CYP2B enzyme activity was unaffected by nitrapyrin, but incubation of phenobarbital-induced rodent liver microsomes with increasing concentrations of nitrapyrin confirmed that nitrapyrin blocked the activity of CYP2B isoforms, possibly via competitive inhibition or action as a suicide substrate. Hepatocellular proliferation (KE3) was observed after 4, 7 or 14 days of compound exposure based on the BrdU labelling index, again at dose levels of ≥250 mg/kg/day. In a recovery group, all of the effects seen after 7 or 14 days treatment at ≥250 mg/kg/day were absent, thus demonstrating reversibility of the key and associative events. Increased incidences of foci of altered hepatocytes and adenomas/carcinomas were observed in the top dose (250 mg/kg/day) of mice following lifetime exposure (2 years) to nitrapyrin (LaRocca et al., 2017) . All of the demonstrated Key Events and Associative Events were unaffected or very small in magnitude at 75 mg/kg/day (e.g., there was a small increase in Cyp2b10 mRNA), which was concordant with the lack of an increased tumor incidence at this dose level.
The short-term effects of nitrapyrin were also evaluated in CAR KO mice after treatment at 250 mg/kg/day. As shown in Table 5 , absence of CAR resulted in no increases in Cyp2b10 mRNA levels or cell proliferation, thus confirming the key events (KE1, KE2 and KE3) were dependent on CAR. Interestingly, hepatocellular hypertrophy (slight or very slight) was still observed in 6/6 CAR KO mice, along with a slight vacuolation of hepatocytes that was previously seen in the wild-type mice as well (data not shown). Consistent with this slight effect on liver histopathology, relative liver weights were 1.2-fold higher than controls on Day 4 for both the CAR KO mice and the wild type mice. In contrast, histopathology of the wild type mice included 5/6 mice with increased mitotic figures, which was not observed in the CAR KO mice. This difference is concordant with the lack of an effect on BrdU labelling index as a marker of cell proliferation in the CAR KO mice. The slight effects of nitrapyrin on hypertrophy and liver weight in CAR KO mice were attributed to compensatory AhR/Cyp1a1 induction in those animals lacking CAR. While no appreciable Cyp1a1 induction was noted in wild type animals (∼3-fold), the CAR KO mice demonstrated a moderate (∼100-fold) induction after nitrapyrin administration. The molecular and liver weight changes in the CAR KO mice were not part of the causal sequence of steps that led to liver tumors, since the Key Events (KE1, KE2, KE3) were all absent in the CAR KO mice.
Alternative MoAs for the nitrapyrin induced hepatic tumors were considered during the course of the mechanistic investigations but dismissed as indicated below:
• DNA Reactivity: All tests (in vitro and in vivo) for genotoxicity were negative. In addition the late onset of tumor formation is not consistent with a genotoxic MoA.
• Activation of other nuclear receptors: In the MoA study, no increase in transcript levels of genes associated with AhR (Cyp1a1) and PPARα (Cyp4a10) were observed. In addition, no differences were observed in a marker of PXR activation (Cyp3a11).
• Cytotoxicity: No changes in relevant clinical chemistry parameters and no diffuse hepatic necrosis were observed.
• There was no histopathological evidence in any rodent study indicating that the hepatic tumors could be due to an increase in apoptosis, statins, metals or an infection.
• Finally, a CAR-mediated MoA was further supported by demonstrating that CAR KO mice, when exposed to a dose level similar to the tumorigenic dose level (250 mg/kg/day), were refractory to the early liver Key Events observed in the mice (LaRocca et al., 2017) .
Finally, experiments were conducted with nitrapyrin in primary hepatocyte cultures from male CD-1 mice (1, 3, 10 and 30 μM) and humans (3, 10, 30 and 100 μM) to investigate the species differences in early key events. The top dose in murine hepatocytes was limited by cytotoxicity, as indicated by greater than 30% decrease in MTT compared to the control. The measure of cell proliferation as determined by DNA synthesis via the EdU labelling index was only increased in mouse hepatocytes and not in human hepatocytes (see LaRocca et al., 2017) . Thus, consistent with prior published studies, the CAR-mediated MoA for nitrapyrin was confirmed to be non-relevant to humans, based on qualitative differences in the response within the hepatocytes (Elcombe et al., 2014) .
Case study 2 -metofluthrin tumor MoA in rats
The dose concordance and time concordance of data in male Wistar rats that support its MoA via CAR activation are presented in Table 6 . Metofluthrin has produced an increase in liver tumors via a CAR activation MoA in male Wistar rats (900 and 1800 ppm) and female Wistar a Nitrapyrin demonstrated to be mechanism-based (suicide) inhibitor of CYP2B10 activity (PROD). b CYP2B10 qualitatively assessed by Western Blot of nitrapyrin-treated liver microsomes. c Data are presented for panlobular (summed) labelling indices. d Incidence of altered foci include basophilic and eosinophilic foci. e Relevant study-specific control incidence of liver adenomas and carcinomas in male mice was 17/50. f In addition to the results shown under KE1 on Day 14, the following endpoints were similarly affected on Day 7: ↑ Cyp2b10 mRNA, ↑ hepatocellular hypertrophy, ↑ relative liver weight (treatment-related effects at 250 and 400 mg/kg/day). g Recovery groups evaluated following a 21-day recovery period showed no effects on the following parameters: Cyp2b10 mRNA, CYP2B10 protein, hepatocellular hypertrophy, and relative liver weight. R.C. Peffer et al. Regulatory Toxicology and Pharmacology 96 (2018) 106-120 rats (1800 ppm), but it did not produce liver tumors in CD-1 mice (Yamada et al., 2009 ). For illustration, Table 6 shows dose-response and time concordance of liver tumors with metofluthrin in male Wistar rats. Investigative studies were conducted at dose levels from 200 ppm (the tumor NOAEL) up to 3600 ppm [a dose considered in excess of the Maximum Tolerated Dose (MTD)] (Deguchi et al., 2009; Hirose et al., 2009) . The key events of Cyp2b1/2 and/or Cyp3a1 mRNA levels (as markers for CAR activation), and increased cell proliferation were each observed after 7 days of treatment at the tumorigenic dose levels of 900 ppm and above. Associative events of increased PROD activity, increased CYP2B protein levels, hepatocellular hypertrophy and increased liver weight were increased at tumorigenic dose levels, but they were unaffected at 200 ppm, the tumor NOAEL. After 14 days of treatment, Cyp2b1/2 mRNA expression and relative liver weight were still increased at a test dose of 2700 ppm metofluthrin, but cell proliferation by BrdU labeling index was no different from control (Deguchi et al., 2009) . In isolated rat hepatocyte cultures treated with 50 μM metofluthrin, co-administration of siRNA for CAR (a gene silencing technique) caused a knockdown of CAR and resulting suppression of the response to metofluthrin (50 μM) for Cyp2b1 mRNA and Car mRNA (Deguchi et al., 2009) . In primary cultures of human hepatocytes, 50 μM metofluthrin produced a 2.4-fold induction of CYP2B6 and increased PROD activity (a marker of CYP2B activity). However, at concentrations from 10 to 1000 μm, no changes in cell proliferation (via BrdU labelling index) were noted in experiments with two different human donors (Hirose et al., 2009; Yamada et al., 2015) . Metofluthrin also failed to increase the expression level of Ki67 mRNA, a cell proliferation-related gene, in human hepatocytes. In contrast, male Wistar rat hepatocytes treated with metofluthrin showed statistically significant increases in BrdU labelling index at concentrations of 10 μM and above, and it also increased the expression of Ki67 mRNA. Increased altered foci (primarily eosinophilic or mixed) were observed in male rats at 900 and 1800 ppm treated for 2 years (Deguchi et al., 2009) . Published studies and analysis of existing data have demonstrated that alternative MoAs for liver tumors can be excluded with metofluthrin (Deguchi et al., 2009; Yamada et al., 2009) , including the analyses shown below.
• Genotoxicity: metofluthrin was negative in a series of genotoxicity studies.
• Cytotoxicity: metofluthrin was not cytotoxic to hepatocytes (dosed up to 1000 μM) and did not show histopathology evidence of cytotoxic effects in vivo (e.g., no necrosis, fibrosis, inflammation).
• PPARα activation and AhR activation: metofluthrin did not produce CYP induction that would indicate activation of PPARα (e.g., Cyp4a isoforms) or AhR (e.g., Cyp1a isoforms) in microarray analysis (Deguchi et al., 2009) . It also did not induce the formation of peroxisomes in vivo (including examination by electron microscopy).
• Estrogenic MoA: across the full database of toxicology studies, metofluthrin did not show evidence of alterations that would signal an estrogenic effect.
• Metal overload: no histopathology evidence of deposition of metals, nor subsequent cell death, were observed.
In summation, the MoA for metofluthrin liver tumors in Wistar rats has been demonstrated based on dose-concordant data for each of the major key events. At the tumor NOAEL of 200 ppm, none of the associative events or key events were observed in vivo. The CAR dependency of the effects of metofluthrin were demonstrated (in part) based on Fig. 2 . Comparison of microarray data for cyproconazole in male CD-1 mice to the CAR biomarker signature via a running Fisher's p-value. Cyproconazole was administered to groups of male CD-1 mice for 30 days at dose levels of 0 (control), 50, 100 and 200 ppm in the diet. Livers were evaluated on Affymetrix mouse microarrays, and a DEG list was obtained based on a minimum fold-change value (1.5) and a statistical significance test (Oshida et al., 2015a for details). The DEG list was compared to the CAR biomarker signature (Oshida et al., 2015a) in NEXTBIO. com [now called Correlation Engine (Illumina)]. It was also compared to the biomarker signatures for model activators of AhR and PPARα (Oshida et al., 2015b (Oshida et al., , 2015c . A Running Fisher's p-value was determined for each comparison; -log (p-value) of > 4 is considered to be a significant match for the signature. In cases where significant changes to genes in the opposite direction vs. the model activators are observed, the -log (p-value) in the graph was assigned a negative value. See Supplemental File 1 for further descriptions of this technique. Yamada et al., (2009) . Control group tumor incidence was 1/50. c Deaths and significant clinical signs occurred at 3600 ppm, indicating 3600 ppm was in excess of MTD. d BrdU labelling index for a 2700 ppm metofluthrin group was significantly increased at 7 days (4-fold), but no different from controls at 14 days (Deguchi et al., suppression of two markers (Cyp2b1 mRNA and Car mRNA) by siRNA co-treatment of rat hepatocytes in vitro. Alternative MoAs can reasonably be excluded for metofluthrin based on additional measurements in the course of the MoA studies. In addition, the human non-relevance of the proposed MoA for metofluthrin was confirmed experimentally based on lack of a cell proliferation response in primary human hepatocytes (in vitro). Very recently, a uPA/SCID chimeric mouse model containing human hepatocytes similar to that described in Yamada et al. (2014) was treated for up to 7 days with 1800 ppm metofluthrin (Okuda et al., 2017) . In three separate experiments using human hepatocytes from three different human donors, 1800 ppm metofluthrin produced a modest induction of human CYP2B6 mRNA, but no increase in replicative DNA synthesis as determined by BrdU labelling in the human liver cells. This result with chimeric mice containing human hepatocytes further confirms the lack of responsiveness of human hepatocytes to the proliferative effects that are a key event leading to rodent liver tumors with metofluthrin.
Discussion
Current methods for investigating the MoA for rodent liver tumors and providing a sufficient weight of evidence to establish a MoA via CAR activation have been outlined in this paper, based on both the current scientific knowledge about CAR activation (Elcombe et al., 2014; Lake et al., 2015) and experience in exploring MoA studies for the registration of pesticidal active ingredients with regulatory agencies globally. A proscriptive, box-checking approach to the question of what data is sufficient to demonstrate this rodent MoA via CAR cannot be applied uniformly across all species, strains and test items, because of inherent differences that result based on these variables. However, by drawing from a recommended suite of endpoints, assays and studies (both in vivo and in vitro), a suitable dataset for a new molecule suspected of acting via a CAR MoA can be obtained (Table 2) . Also, it must be understood that as new methods emerge and become more widely used, the exact set of studies and endpoints that are used to demonstrate the key events and associative events will evolve. In fact, greater scientific understanding of the mechanisms that are operative during short-term through long-term treatments with CAR-activating compounds may result in changes to the sequence of key events that are considered part of the CAR MoA. It is also worth considering that for certain chemical classes (e.g. triazole fungicides), where extensive data have been generated that demonstrate liver tumors occur via a CAR MoA, a much simpler set of studies should be acceptable to confirm that a new molecule in this same chemical class is also operating via a CAR MoA (Currie et al., 2014; Oshida et al., 2015a; Peffer et al., 2007) .
Some of the newer methods that have been utilized recently, or that show promise for the future, have been summarized as well (Supplemental File S1). Chimeric liver humanized mouse models constitute one novel method that has shown promise in being able to investigate key events within a human liver in vivo (albeit a human liver reconstituted within an immune-compromised mouse model) (Scheer and Wilson, 2016; Yamada et al., 2014) , and experiments with PB in these systems have demonstrated that the human hepatocytes do not undergo cell proliferation. This is consistent with what has been seen in primary hepatocyte cultures, as well as in non-rodent in vivo models, such as the Syrian hamster (Diwan et al., 1986; James and Roberts, 1996) . While such models are promising as research tools, the relatively high cost (currently) of these chimeric mice, the extensive manipulations of the animals that are required to generate the model and possible confounders in the model (e.g., immune deficiency, the need to administer additional agents such as GH, NTBC, etc.) suggests that they may not be appropriate at present for widespread use when exploring a CAR MoA for a new test compound.
The promise of other new technologies to reduce animal use and/or replace them with in vitro tests or analysis of existing in vivo tissues from the subchronic guideline studies is also worth further consideration. In particular, a CAR biomarker signature in mice has been described that relies not just on a limited number of 3-4 genes, but on an 83-gene signature derived from multiple CAR activating compounds (Oshida et al., 2015a) . As shown in Fig. 2 , this biomarker signature provides a strong statistical match for a known CAR-activating mouse liver tumorigen (cyproconazole) that was not part of the training dataset. Further, the CAR signature can be applied following treatment of different mouse strains, treatment durations, and genomic platforms with reasonable assurance that a statistical match is likely to be detectable, and that several alternative MoAs (e.g., AhR, PPARα) can be excluded based on their biomarker signatures ( Fig. 2 ; Oshida et al., 2015b; Oshida et al., 2015c) . Hopefully, as tools like this become more widely used for regulatory data submissions, the level of confidence to make a conclusion on the MoA being via CAR activation based on its biomarker signature will become greater, if the data sets show good concordance. With careful foresight, it may be possible in the near future to generate the data to establish that a compound is operating via a CAR MoA using properly stored tissues from earlier subacute and subchronic toxicology studies that are part of the normal progression of regulatory studies for that molecule. Possible in vitro assays that may complement the biomarker signature approach, and perhaps eventually replace large-scale animal use for MoA work, include the CAR3 reporter assays that have shown a good ability to distinguish species-specific CAR activators for mouse, rat and human CAR (Omiecinski et al., 2011) .
Conclusions
A minimum data set to adequately demonstrate that a test compound operates via the known MoA of CAR activation can be drawn from a currently available toolbox of in vivo and in vitro assays (illustrated in Tables 2 and 3) . A typical data set includes a short-term (1-28 days) MoA study in the same strain of mouse/rat as the cancer study, as well as various endpoints to demonstrate KE1 (CAR activation), KE2 (altered gene expression secondary to CAR activation) and KE3 (cell proliferation). Studies in genetically modified mice/rats are not required, however, they can be helpful; for example, experiments in CAR/PXR KO mice that show either an absence or significant attenuation of some key events is one way to demonstrate that CAR activation (KE1) is operative. Measurements should be included in the short-term MoA study to disprove alternative MOAs (e.g., that AhR, PPARα and cytotoxicity followed by regenerative hyperplasia are not the primary causal events). In vitro studies using primary cultures of hepatocytes (rodent, human) are not required, but based on current practice and regulatory feedback, most registrants may want to include these. They should measure 1) cell proliferation (KE3), and 2) some measure to show increased markers of CAR activation such as Cyp2b isoform mRNA levels, or PROD and/or BROD activities. There are other ways to show KE1, KE2 and the associative event AE1 (increased Cyp2b and Cyp3a enzyme activity and/or protein) are operative in a MoA data set, including in vitro CAR reporter assays with mouse, rat and human CAR. Extensive data exist with known CAR-activating compounds that show a fundamental qualitative difference between the species, and indicate that the key events leading to tumors in mice or rats are not operative in humans. Therefore, a data set such as those suggested in this paper for a test compound should lead to a conclusion that the MoA for rodent liver tumors is non-relevant to human risk assessment.
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